MedCity News March 7, 2025
J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder. The disappointing result follows the Phase 3 failure of a Neumora Therapeutics drug that addresses the same central nervous system target.
A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of medicines addressing a novel target hoped to overcome limitations of currently available antidepressants.
J&J is discontinuing the Phase 3 test of its drug, aticaprant, in major depressive disorder “due to insufficient efficacy in the target patient population,” the company said after Thursday’s market close. The pharmaceutical giant said this drug was safe...
Today's Sponsors
Today's Sponsor